Finally, follow-up plasma samples during treatment and determination of LOX activity could reflect a response to treatment through decrease in LOX activity as one might hypothesize in AML and in patients with extramedullary AML, specifically. The gene discussed is LOX; the disease is acute myeloid leukemia.